Joshua May
Psychiatry · Wellington, FLNPI 1205037553
Payments from drug & device makers
Across 215 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$834
- AbbVie$632
- Corium, LLC$531
- Lundbeck LLC$363
- Supernus Pharmaceuticals, Inc.$252
- Merck$179
- plus $747 from 15 others
What the payments were for
- Food & beverage$3,537100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 53 | $834 |
| AbbVie | 37 | $632 |
| Corium, LLC | 41 | $531 |
| Lundbeck LLC | 22 | $363 |
| Supernus Pharmaceuticals, Inc. | 15 | $252 |
| Merck | 11 | $179 |
| Teva Pharmaceuticals USA, Inc. | 6 | $146 |
| Johnson & Johnson | 7 | $134 |
| Axsome Therapeutics, Inc. | 3 | $92 |
| Bausch Health US, LLC | 3 | $55 |
| Otsuka America Pharmaceutical, Inc. | 3 | $53 |
| Tris Pharma Inc | 3 | $51 |
| Eisai Inc. | 2 | $38 |
| Boston Scientific | 1 | $34 |
| Neos Therapeutics, LP | 2 | $33 |
| Idorsia Pharmaceuticals US Inc | 1 | $24 |
| Vanda Pharmaceuticals Inc. | 1 | $20 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $20 |
| Adlon Therapeutics L.p. | 1 | $18 |
| Shire North American Group Inc | 1 | $15 |
| Almatica Pharma LLC | 1 | $13 |
How this compares
$3,537 in reported general payments places this provider in the 75th percentile of 2,059 psychiatry providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrintellixVortioxetine Hydrobromide | 36 | $22,814 |
| Fluoxetine Hcl | 49 | $1,379 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 28 | $1,219 |
| Quetiapine Fumarate | 47 | $760 |
| Bupropion XlBupropion Hcl | 26 | $704 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 20 | $668 |
| Clonazepam | 64 | $635 |
| Alprazolam | 81 | $595 |
| Zolpidem Tartrate | 34 | $439 |
| Duloxetine Hcl | 16 | $422 |
| Mirtazapine | 20 | $311 |
| Buspirone Hcl | 23 | $254 |
| Gabapentin | 17 | $249 |
| Lorazepam | 25 | $225 |
| Lamotrigine | 29 | $182 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $834 | $22,81436 claims |
| Almatica Pharma LLCSertraline Hcl | $13 | $18123 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Wellington
- Edwin GomezWeston$24.9M
- Rishi KakarTamarac$23.9M
- Peter VentreOakland Park$18.7M
- Jose GamezHialeah$14.8M
- John JoyceJacksonville$13.6M
- Silvia Silva-DulucMiami$11.7M
- Kelley WilsonTampa$11.1M
- Emilio Mantero-AtienzaMiami Beach$10.9M
- Patricia JunqueraMiami$10.8M
- Olga LapeyraLauderhill$10M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.